Murine Models for Studying the Pathogenesis and Treatment of Pyelonephritis

  • Prabhavathi B. Fernandes
  • Nathan L. Shipkowitz
  • Robert R. Bower
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 224)


A variety of animal models have been used to study the pathogenesis and treatment of pyelonephritis in man. These models have employed a variety of animals such as monkeys, rabbits, guinea pigs, rats, and mice, and have been extensively reviewed by Cotran (1).


Urinary Tract Infection Antibacterial Agent Infection Level Median Effective Dose Urinary Tract Infec 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.S. Cotran. Experimental pyelonephritis, in: “The Kidney: Morphology, Biochemistry, Physiology”, C. Roullier, A.F. Muller, ed.Vol. II. Academic Press, New York (1969).Google Scholar
  2. 2.
    C.P. Adler, H. Ritzman, and H.U. Zollinger, Vergleichende Untersuchungen über die hamatogene und die ascendierende pyelonephritis bei ratten, Virchows Arch [Pathol Anat]: 347: 277 (1969).CrossRefGoogle Scholar
  3. 3.
    A.I. Baude, A. P. Shapiro, and J. Siemienski, Hematogenous pyelonephritis in rats III. Relationship of bacterial species to the pathogenesis of acute pyelonephritis, J. Bacterial. 77: 270 (1959).Google Scholar
  4. 4.
    R.S. Cotran, E., Vivaldi, D.P., Zangwill, and E. H. Kass, Retrograde Proteus pyelonephritis in rats, Bacteriologie, pathologic, and fluorescent-antibody studies. Am. J. Pathol. 43: 1 (1963).PubMedGoogle Scholar
  5. 5.
    R.H. Heptinstall. Experimental pyelonephritis. Bacteriological and morphological studies on the ascending route of infection in the rat. Nephron. 1: 73 (1964).PubMedCrossRefGoogle Scholar
  6. 6.
    B.W. Hunter, L.L., Souda, and J.P. Sanford. Antibiotic therapy in established chronic experimental Proteus mirabilis pyelonephritis, Antimicrob. Agents Chemother. 3; 608 (1963).Google Scholar
  7. 7.
    T.E. Miller, and K.B. Robinson. Experimental pyelonephritis: a new method for inducing pyelonephritis in the rat, J. Infect. Dis. 127: 307 (1973).PubMedCrossRefGoogle Scholar
  8. 8.
    J.D. Sobel, and D. Kaye. Host factors in the pathogenesis of urinary tract infections. Am. J. Med. 76: 122 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    L. Hagberg, I. Engberg, R. Freter, J. Lam, S. Oiling, and C. Svanborg-Eden., Ascending unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect. Immun. 40: 273 (1983).PubMedGoogle Scholar
  10. 10.
    L.R. Freedman. Experimental pyelonephritis XIII. On the ability of water diuresis to induce susceptibility to E, coli bacteriuria in the normal rat, Yale J. Biol. Med. 39: 255 (1967).PubMedGoogle Scholar
  11. 11.
    W. Henkel, and R., Commichau. Serumresistenz und nephropathogenitar antigenetisch difinierter Stamme von E. coli III, Experimentelle pyelonephritis mit unterschiedlick serum-resistenten keimen, Z. med. Mikrobiol. Immunol. 156: 297 (1971).PubMedCrossRefGoogle Scholar
  12. 12.
    D. Kaye. Antibacterial activity of human urine, J. Clin. Invest. 47: 2374 (1968).PubMedCrossRefGoogle Scholar
  13. 13.
    M. Aronson, O. Medalia and B. Griffel. Prevention of ascending pyelonephritis in mice by urease inhibitors. Nephron 12: 94 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    CG. Cobbs, and D., Kaye. Antibacterial mechanisms in the urinary bladder, Yale J. Biol. Med. 40: 93 (1967).PubMedGoogle Scholar
  15. 15.
    P.B. Beeson, and D. Rowley. The anticomplementary effect of kidney tissue. Its association with ammonia production, J. Exp. Med. 110: 685 (1959).PubMedCrossRefGoogle Scholar
  16. 16.
    R.N. Gruneberg, D.A. Leigh, and W. Brumfitt. Escherichiau coli serotypes in urinary tract infection, in: Studies in domiciliary antenatal and hospital practice in urinary tract infections,” F. O’Grady and W. Brumfitt, ed., Oxford University Press, London (1968).Google Scholar
  17. 17.
    B. Kusecek, H. Wloch, A. Mercer, V. Vaisanen, G. Pluschke, T. Korhonen, and M. Achtman. Lipopolysaccharide, capsule, and fimbriae as virulence factors among 01, 07, 016, 018, 04 075 and Kl, K5, or Kl00 Escherichia coli. Infect. Immun. 43: 368 (1984).PubMedGoogle Scholar
  18. 18.
    J.F. Van der Bosch, U. Verboom-Sohmer, P. Postma, J. DeGraäff and D. MacLaren, Mannose-sensitive and Mannose-resistant adherence to human uroepithelial cells and urinary virulence of Escherichia coli. Infect. Immun. 29: 226 (1980).PubMedGoogle Scholar
  19. 19.
    L. Hagberg, U. Jodal, T.K. Korhonen, G. Lidin-Janson, U. Lindberg, and C. Svanborg-Eden. Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections, Infect. Immun. 31: 564 (1981).Google Scholar
  20. 20.
    C. Svanborg-Eden, B. Eriksson, and L.A. Hanson. Adhesion of Escherichia coli to human uroepithelial cells in vitro. Infect. Immun. 18: 767 (1977).Google Scholar
  21. 21.
    I. Ofek, A. Mosek, and N. Sharon. Mannose-specific adherence of Escherichia coli freshly excreted in the urine of patients with urinary tract infections, and of isolates subcultured from the infected urine. Infect. Immun. 34: 708 (1981).PubMedGoogle Scholar
  22. 22.
    M. Aronson, O. Medalia, L. Schori, D. Mirelman, N. Sharon, and I. Ofek. Prevention of colonization of the urinary tract of mice with Escherichia coli by blocking of bacterial adherence with methyl -D-mannopyranoide, J. Infect. Dis. 139: 329 (1979).PubMedCrossRefGoogle Scholar
  23. 23.
    L. Hagberg, R. Hull, S. Hull, S. Falkow, R. Freter, and C. Svanborg-Eden. Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect. Immun. 40: 265 (1983).PubMedGoogle Scholar
  24. 24.
    C. Svanborg-Eden, R. Freter, L. Hagberg, R. Hull, S. Hull, H. Leffler, G. SchooInik. Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (London) 298: 560 (1982).CrossRefGoogle Scholar
  25. 25.
    Varsanen, V., L.G. Tallgren, P.H. Makela, G. Kallenius, H. Hultberg, J. Elo, A. Siitonen, C. Svanborg-Eden, S.B. Svenson, and T. Korhonen, Mannose-resistant haemagglutination and P antigen recognition are characteristic of Escherichia coli causing primary pyelonephritis. Lancet. II: 1366 (1981).CrossRefGoogle Scholar
  26. 26.
    G. Kallenus, R. Mollby, H. Hultberg, S.B. Svenson, B. Cedergren, and J. Winberg, 1981. Structure of carbohydrate part of receptor on human uroepithelial cells for pyelonephritogenic Escherichia coli. Lancet II: 604 (1981).CrossRefGoogle Scholar
  27. 27.
    H. Leffler, and C. Svanborg-Eden. Chemical identification of a glycospingolipid receptor for Escherichia coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes, FEMS Microbiol. Lett. 8: 127 (1980).CrossRefGoogle Scholar
  28. 28.
    C. Svanborg-Eden, L.M. Bjursten, R. Hull, S. Hull, K.E. Magnussen, Z. Moldovano, and H. Leffler. Influence of adhesin on the interaction of Escherichia coli with human phagocytes. Infect. Immun. 44: 672 (1984).PubMedGoogle Scholar
  29. 29.
    U.L. Lindberg, A. Hanson, U. Jodal, G. Lidin-Janson, K. Lincoln, and S. Oiling. Asymptomatic bacteriurea in school girls, II. Differences in Escherichia coli causing asymptomatic bacteriuria, Acta. Paediatr. Scand. 64: 432 (1975).PubMedCrossRefGoogle Scholar
  30. 30.
    S. Oiling, L.A. Hanson, J. Holmgen, U. Jodel, K. Lincoln and U. Lindberg. The bactericidal effect of normal human serum on E, coli strains from animals and from patients with urinary tract infections, Infection 1: 24 (1973).CrossRefGoogle Scholar
  31. 31.
    A. Glynn, A. Brumfitt, and C.J. Howard. Kantigens of Escherichia coli and renal involvement in urinary tract infections. Lancet 1: 514 (1971).PubMedCrossRefGoogle Scholar
  32. 32.
    J.W. Smith, and B. Kaijser. The local immune response to Escherichia coli O and K antigen in experimental pyelonephritis, J. Clin. Invest. 58: 276 (1976).PubMedCrossRefGoogle Scholar
  33. 33.
    B. Herrmann, and L.G. Burman. Chemoattracting effect of human urine on motile Escherichia coli, FEMS Microbiol. Lett. 20: 411 (1983).CrossRefGoogle Scholar
  34. 34.
    G.M. Kalmanson, M. Turck, H.J. Harwick, and L.B. Guze. Urinary tract infection: Localization and virulence of Escherichia coli, Lancet 1: 134 (1975).PubMedCrossRefGoogle Scholar
  35. 35.
    D. Low, V. David, D. Lark, G. Schoolnik, and S. Falkow. Gene cluster governing the production of hemolysin and mannose-resistant hemaglutination are closely linked in Escherichia coli serotype 04 and 06 isolates from urinary tract infections, Infect. Immun. 43: 353 (1984).PubMedGoogle Scholar
  36. 36.
    R.M. Al-Ssum, and D.M. Harris. The contribution of diffusable toxins of Pseudomonas aeruginosa to the pathogenesis of experimental pyelonephritis, J. Infect. 4: 49 (1982).PubMedCrossRefGoogle Scholar
  37. 37.
    B. Kaijser, P. Larsson, and S. Oiling. Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity, Infect. Immun. 20: 78 (1978).PubMedGoogle Scholar
  38. 38.
    J.P. Sanford, B.W. Hunter, and L.L. Souda. The role of immunity in the pathogenesis of experimental hematogenous pyelonephritis, J. Exp. Med. 115: 383 (1962)PubMedCrossRefGoogle Scholar
  39. 39.
    B. Kaijser. Immunology of Escherichia coli: K antigen and its relation to urinary tract infection, J. Infect. Dis. 127: 670 (1973).PubMedCrossRefGoogle Scholar
  40. 40.
    I. Mattsby-Baltzer, L.A. Hanson, S. Oiling, and B. Kaijser. Experimental Escherichia coli ascending pyelonephritis in rats: Active peroral immunization with live Escherichia coli. Infect. Immun. 35: 647 (1982).PubMedGoogle Scholar
  41. 41.
    F.H. Millazo, and G.J. Delisle. Immunoglobulin A proteases in gram-negative bacteria isolated from human urinary tract infections. Infect. Immun. 43: 11 (1984).Google Scholar
  42. 42.
    C. Svanborg-Eden, D. Briles, L. Hagberg, J. McGhee, and S. Michalec. Genetic factors in host resistance to urinary tract infection. Infection 12: 118 (1984).PubMedCrossRefGoogle Scholar
  43. 43.
    H. Pitchon, R. Glassock, G.M. Kalmanson, and L.B. Guze. Experimental pyelonephritis: The effect of T-cell deficiency in the course of hematogenous enterococcal pyelonephritis in the mouse. Am. J. Pathol. 115: 25 (1984).PubMedGoogle Scholar
  44. 44.
    C. Svanborg-Eden, B. Andersson, L. Hagberg, L.A. Hanson, H. Lemberg, H. Leffler, G. Magnussen, G. Noori, J. Dahmen, and T. Sonderstrom. Receptor analogues and anti-pili antibodies as inhibitors of bacterial attachment in vivo and vitro, Proc. N.Y. Acad. Sei. 409: 580 (1983).CrossRefGoogle Scholar
  45. 45.
    T. Nishi, and K. Tsuchiya. Experimental urinary tract infection with Pseudomnonas aeruginosa in mice. Infect. Immun. 22: 508 (1978).PubMedGoogle Scholar
  46. 46.
    W.P. Keane, and L.R. Freedman. Experimental pyelonephritis XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis, Yale J. Biol. Med. 40: 231 (1967).PubMedGoogle Scholar
  47. 47.
    L.B. Guze, F. Silverblatt, J.Z. Montogomerie, K. Ishida, and G.M. Kalmanson. Lack of significance of pili in ascending Escherichia coli pyelonephritis, Scand. J. Infec. Dis. 15: 57 (1983).Google Scholar
  48. 48.
    E.G. Hubert, G.M. Kalmanson and L.B. Guze. Antibiotic therapy of Escherichia coli pyelonephritis produced in mice undergoing chronic diuresis, Antimicrob. Agents. Chemother. 8: 507 (1968).PubMedGoogle Scholar
  49. 49.
    M. Rocha, and F.R. Fekety. Acute inflammation in the renal cortex and medulla following thermal injury, J. Exp. Med. 119: 131 (1964).PubMedCrossRefGoogle Scholar
  50. 50.
    E.H. Thiele. An in vivo pyelonephritis assay for screening therapeutic agents, J. Antibiot. 27: 31 (1984).CrossRefGoogle Scholar
  51. 51.
    O. Zak, F. Kradolfer, E.A. Konopka, S. Kunz and E. Batt. CGP7174/E (Takeda SCE 129), Activity against systemic and urinary tract infections in mice and rats, in “Current Chemotherapy”, Vol 2. Proceedings of the 19th International Congress of Chemotherapy, Zurich, ASM, Washington, D.C. 846 (1978).Google Scholar
  52. 52.
    A.Q. Thomson, and E.F. Fowler, Carrageenan: A review of its effects on the immune system. Agents and Actions 11 (3): 265 (1981).PubMedCrossRefGoogle Scholar
  53. 53.
    E.F. Fowler, J.G. Simpson and A.W. Thomson. Histological and ultrastructural changes following carageenan injection in the mouse, J. Path. 132: 63 (1980).PubMedCrossRefGoogle Scholar
  54. 54.
    R. MoeHering. Enterococcal infections in patients treated with moxalactam. Rev. Infect. Dis. 4: S708 (1982).CrossRefGoogle Scholar
  55. 55.
    J. Fletcher, and E. Goldstein. The effect of parenteral iron preparations on experimental pyelonephritis, Br. J. Exp. Pathol. 51: 280 (1970).PubMedGoogle Scholar
  56. 56.
    K.R. Comber. Pathogenesis of an experimental pyelonephritis model in the mouse and its use in the evaluation of antibiotics, in: “Chemotherapy”, Vol 2, J.D., Williams and A.M. Gedes, ed.. Plenum Publishing Corp., New York (1976).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Prabhavathi B. Fernandes
    • 1
  • Nathan L. Shipkowitz
    • 1
  • Robert R. Bower
    • 1
  1. 1.Pharmaceutical Products DivisionAbbott LaboratoriesNorth ChicagoUSA

Personalised recommendations